Clinical Trial Update: Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

View source ↗

Summary

A clinical trial evaluating amyloid and glucose PET imaging in Alzheimer’s disease and vascular cognitive impairment patients with significant white matter dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cerebral Small Vessel Disease
• Vascular Cognitive Impairment

Snippet

Sponsor: Dr. Sandra E Black | Conditions: Alzheimer's Disease, Small Vessel Disease White Matter Hyperintensities Subtype | Status: COMPLETED